公开(公告)号：US20210100872A1

公开(公告)日：2021-04-08

申请号：US16956109

申请日：2018-12-11

Applicant: Novmetapharma Co., Ltd.

Inventor： Heon Jong Lee ,  Kay Olmstead ,  Moon Ki Song ,  Kyong-Tai Kim ,  In-Kyu Lee ,  Hoe-Yune Jung

IPC: A61K38/12 ,  A61K33/30 ,  A61P3/10 ,  A61K9/48

Abstract: The present invention relates to a pharmaceutical formulation for preventing or treating diabetes mellitus, comprising cyclo-hispro as an active ingredient. Specifically, the present invention has the effect of lowering the concentration of glycated hemoglobin (HbA1c) in the blood, and further improving leptin resistance. In addition, the present invention relates to a pharmaceutical formulation for preventing or treating diabetes mellitus, characterized in that the pharmaceutical formulation comprises cyclo-hispro and zinc and is administered once a day.

公开(公告)号：US11975041B2

公开(公告)日：2024-05-07

申请号：US16764913

申请日：2018-11-20

Applicant: NovMetaPharma Co., Ltd.

Inventor： Hoe Yune Jung ,  Heon Jong Lee ,  Do Hyun Lee

IPC: A61K38/00 ,  A61K35/52 ,  A61K38/12 ,  A61P19/10

CPC classification number: A61K38/12 ,  A61K35/52 ,  A61P19/10

Abstract: A composition containing cyclo-hispro (CHP) and its use in preventing, alleviating, or treating bone loss diseases are disclosed. The composition contains CHP or a CHP-containing prostate extract.

公开(公告)号：US11413270B2

公开(公告)日：2022-08-16

申请号：US16908195

申请日：2020-06-22

Applicant: NOVMETAPHARMA CO., LTD.

Inventor： Heon Jong Lee ,  Hoe Yune Jung ,  In-Kyu Lee ,  Jae-Han Jeon ,  Sung Jin Cho

IPC: A61K31/397 ,  A61K31/495 ,  A61K31/4453 ,  A61K31/5375 ,  A61K31/4025 ,  A61P1/18 ,  A61K31/454 ,  A61K31/407 ,  A61K31/4525 ,  A61K31/403 ,  A61K31/4192 ,  A61K31/396

Abstract: A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.

公开(公告)号：US20220054541A1

公开(公告)日：2022-02-24

申请号：US17406626

申请日：2021-08-19

Applicant: NovMetaPharma Co., Ltd.

Inventor： Hoe Yune JUNG

IPC: A61K33/30 ,  A61P1/12

Abstract: A new use of a cyclo(His-Pro) is disclosed. In particular, a method for treating inflammatory bowel disease which includes administering an effective amount of an isolated cyclo(His-Pro) or a pharmaceutically acceptable salt thereof to a subject in need thereof is disclosed.

公开(公告)号：US20200345728A1

公开(公告)日：2020-11-05

申请号：US16398421

申请日：2019-04-30

Applicant: NovMetaPharma Co., Ltd. ,  The United States Government as Represented by the Department of Veterans Affairs

Inventor： Moon Ki Song ,  Mysore S. Veena ,  David Scott Bischoff ,  Dean Takao Yamaguchi

IPC: A61K31/4985 ,  A61K33/30 ,  A61P9/10 ,  A61K9/48 ,  A61K9/20

Abstract: The present invention relates to a composition for preventing or treating atherosclerosis in a subject, comprising a zinc salt and cyclo-Hispro and a method of preventing or treating atherosclerosis using thereof.

公开(公告)号：US20200282000A1

公开(公告)日：2020-09-10

申请号：US16759554

申请日：2018-09-20

Applicant: National Institute for Korean Medicine Development ,  NovMetaPharma Co., Ltd.

Inventor： Hyo Jung KIM ,  Sun Gun KIM ,  Jai Hyun SO ,  Hwa Dong LEE ,  Hye Ryung KANG

IPC: A61K36/704 ,  A61K36/54 ,  A61K9/00

Abstract: The present invention relates to an antithrombotic composition including Polygonum cuspidatum Sieb. et Zucc. and Cinnamomum cassia Blume as active ingredients, and preferably includes an extract obtained by mixing Polygonum cuspidatum Sieb. et Zucc. and Cinnamomum cassia Blume in a weight ratio of 1:2-2:1 and extracting the mixture. The composition of the present invention is highly effective in antithrombotic effects, identified as a platelet aggregation inhibitory effect, a thrombosis inhibitory effect, a thrombosis-delaying effect, and the like, and thus can be used as an effective herbal-medicine-based agent for preventing or treating thrombosis, an antithrombotic health food, and the like.

公开(公告)号：US10683300B2

公开(公告)日：2020-06-16

申请号：US16448083

申请日：2019-06-21

Applicant: NovMetaPharma Co., Ltd.

Inventor： Kay Olmstead ,  David Pearson ,  Elaine McPherson

IPC: C07D487/04

Abstract: The present disclosure relates to synthesis and characterization of novel polymorphic forms of Cyclo (-His-Pro) (“CHP”).

公开(公告)号：US20190175583A1

公开(公告)日：2019-06-13

申请号：US16324784

申请日：2017-08-14

Applicant: NOVMETAPHARMA CO., LTD. ,  Postech Academy-Industry Foundation

Inventor： Kyong Tai KIM ,  Hoe Yune JUNG ,  Heon Jong LEE

IPC: A61K31/4706 ,  A61K45/06 ,  A61P3/10 ,  A61P3/04 ,  A61P3/06 ,  A61P1/16 ,  A61P9/00

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes, and controlling a side effect from peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation, wherein the pharmaceutical composition comprises (a) an amodiaquine compound or a pharmaceutically acceptable salt thereof and (b) an antidiabetic drug as active ingredients. Specifically, the composition prevents or treats simultaneously one or more selected from the group consisting of type 2 diabetes reactive to PPAR-gamma activation, and obesity, dyslipidemia, cardiovascular diseases, and fatty cirrhosis reactive to peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activation.

公开(公告)号：US20180042917A1

公开(公告)日：2018-02-15

申请号：US15551310

申请日：2016-02-16

Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATION ,  NOVMETAPHARMA CO., LTD.

Inventor： Kyong Tai KIM ,  Hoe Yune JUNG

IPC: A61K31/4706

CPC classification number: A61K31/4706 ,  A61K31/47 ,  A61P1/16 ,  A61P3/00 ,  A61P3/04 ,  A61P3/08 ,  A61P3/10 ,  A61P9/00 ,  A61P9/12

Abstract: The present invention relates to a novel use of a composition containing, as an active ingredient, an amodiaquine compound or a pharmaceutically acceptable salt thereof and specifically, to a metabolic disease prevention, alleviation or treatment use of a composition containing, as an active ingredient, an amodiaquine compound or a pharmaceutically acceptable salt thereof, the composition activating both peroxisome proliferator-activated receptor-gamma (PPAR-γ) and peroxisome proliferator-activated receptor-alpha (PPAR-α).

公开(公告)号：US20240140955A1

公开(公告)日：2024-05-02

申请号：US18476630

申请日：2023-09-28

Applicant: NOVMETAPHARMA CO., LTD.

Inventor： Heon Jong LEE ,  Hoe Yune JUNG

IPC: C07D487/06

CPC classification number: C07D487/06

Abstract: Novel PEG modified cyclic dipeptide compounds are disclosed. The modified cyclic dipeptide compounds contain a cyclic dipeptide and a biocompatible polymer attached to the cyclic dipeptide. The cyclic dipeptide may be proline-containing, hydroxyproline-, or histidine-containing cyclic dipeptide. In one embodiment, the cyclic dipeptide is a cyclo (-his-pro). Exemplary modified cyclic dipeptide compounds are represented by Formula A′: